Coherus Hoping For Expedited FDA Review Of Pegfilgrastim On-Body
Biosimilar Humira Sales Won’t Accelerate Until 2025; Pleased With Ranibizumab Execution
Coherus BioSciences offered clarity and insight into its three marketed biosimilar products, as the firm continues to await USFDA approval for its pegfilgrastim biosimilar using an on-body injector device.
